These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 9676021

  • 1. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia.
    Mazza P, Amurri B, Lazzari G, Masi C, Palazzo G, Spartera MA, Giua R, Sebastio AM, Suma V, De Marco S, Semeraro F, Moscogiuri R.
    Haematologica; 1998 Jun; 83(6):496-501. PubMed ID: 9676021
    [Abstract] [Full Text] [Related]

  • 2. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW, Ng IO, Chan GC.
    Hemoglobin; 2006 Jun; 30(2):263-74. PubMed ID: 16798652
    [Abstract] [Full Text] [Related]

  • 3. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2008 Jun; 32(1-2):41-7. PubMed ID: 18274982
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and adverse effects of oral iron chelator deferiprone (l1, 1,2- dimethyl-3-hydroxypyrid-4-one) in patients with beta thalassaemia major in Pakistan.
    Ayyub M, Ali W, Anwar M, Waqar A, Khan MN, Ijaz A, Hussain T, Hussain S.
    J Ayub Med Coll Abbottabad; 2005 Jun; 17(4):12-5. PubMed ID: 16599026
    [Abstract] [Full Text] [Related]

  • 5. Iron chelation therapy.
    Hoffbrand AV, Wonke B.
    J Intern Med Suppl; 1997 Jun; 740():37-41. PubMed ID: 9350180
    [Abstract] [Full Text] [Related]

  • 6. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1).
    Rombos Y, Tzanetea R, Konstantopoulos K, Simitzis S, Zervas C, Kyriaki P, Kavouklis M, Aessopos A, Sakellaropoulos N, Karagiorga M, Kalotychou V, Loukopoulos D.
    Haematologica; 2000 Feb; 85(2):115-7. PubMed ID: 10681716
    [Abstract] [Full Text] [Related]

  • 7. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A, Manz C, Naja M, Eltagui M, Tarabishi C, Youssry I, Sobh H, Hamdy M, Sharaf I, Mostafa A, Shaker O, Hoffbrand AV, Taher A.
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [Abstract] [Full Text] [Related]

  • 8. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
    Kolnagou A, Michaelides Y, Kontos C, Kyriacou K, Kontoghiorghes GJ.
    Hemoglobin; 2008 Jul; 32(1-2):17-28. PubMed ID: 18274979
    [Abstract] [Full Text] [Related]

  • 9. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
    Pantalone GR, Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C.
    Hemoglobin; 2011 Jul; 35(3):206-16. PubMed ID: 21599433
    [Abstract] [Full Text] [Related]

  • 10. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload.
    Payne KA, Rofail D, Baladi JF, Viala M, Abetz L, Desrosiers MP, Lordan N, Ishak K, Proskorovsky I.
    Adv Ther; 2008 Aug; 25(8):725-42. PubMed ID: 18704280
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of 1-2, dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload.
    Agarwal MB, Gupte SS, Vasandani D, Viswanathan C, Puniyani RR, Ramanathan J, Massil DE, Shah S, Rajyadhyaksha GC, Bhave AA.
    J Assoc Physicians India; 1991 Sep; 39(9):669-72. PubMed ID: 1814897
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major.
    Aydinok Y, Ulger Z, Nart D, Terzi A, Cetiner N, Ellis G, Zimmermann A, Manz C.
    Haematologica; 2007 Dec; 92(12):1599-606. PubMed ID: 18055982
    [Abstract] [Full Text] [Related]

  • 16. Effect of deferiprone on liver iron overload and fibrosis in hepatitis-C-virus-infected thalassemia.
    Chen AC, Peng CT, Wu SF, Wu KH, Chiang IP, Tsai CH.
    Hemoglobin; 2006 Dec; 30(2):209-14. PubMed ID: 16798645
    [Abstract] [Full Text] [Related]

  • 17. The controversial role of deferiprone in the treatment of thalassemia.
    Richardson DR.
    J Lab Clin Med; 2001 May; 137(5):324-9. PubMed ID: 11329529
    [Abstract] [Full Text] [Related]

  • 18. Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan.
    Peng CT, Wu KH, Wu SF, Liang DC, Yang CP, Jang RC, Wang LY, Hsiao CC.
    Hemoglobin; 2006 May; 30(1):125-30. PubMed ID: 16540425
    [Abstract] [Full Text] [Related]

  • 19. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
    Wu SF, Peng CT, Wu KH, Tsai CH.
    Hemoglobin; 2006 May; 30(2):215-8. PubMed ID: 16798646
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.
    al-Refaie FN, Wonke B, Hoffbrand AV, Wickens DG, Nortey P, Kontoghiorghes GJ.
    Blood; 1992 Aug 01; 80(3):593-9. PubMed ID: 1638018
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.